By 2030, one in six people worldwide will be aged 60 or older. By 2050, that population will reach approximately 2.1 billion people, according to the World Health Organization. Perhaps even more significant, the majority of people aged 60 or older are expected to live in low- and middle-income countries by 2050.
Population ageing is therefore not simply a challenge for established healthcare markets such as Japan, Western Europe, and the United States. It is becoming a global transformation with profound implications for healthcare systems, businesses, and investors.
The population aged 60+ is expanding
Global population aged 60 years and older · billions
Source: WHO, Ageing and health. Patterned bars show projections; all bars start at zero. The 2.1× comparison is calculated from WHO’s rounded population figures.
From longer lives to healthier lives
Increasing life expectancy represents one of humanity’s major achievements. But living longer does not automatically mean living healthier.
Ageing populations bring changing patterns of demand for chronic disease management, cardiovascular care, oncology, neurological conditions, rehabilitation, and long-term support.
The strategic objective should not simply be to extend life. It should be to increase the number of years people can live with good health, independence, and quality of life.
A new healthcare value chain is emerging
Traditional healthcare systems have largely been organized around diagnosing and treating illness. The longevity transition creates opportunities to develop more continuous, preventive, and integrated models of care.
From treatment to prevention. Risk identification, screening, vaccination, lifestyle interventions, and early disease management can play a greater role in maintaining health and functional ability.
From institutions to connected care. Remote monitoring, home-based diagnostics, digital therapeutics, and coordinated community services may help manage chronic conditions outside traditional hospital settings.
From isolated products to integrated solutions. Pharmaceutical, diagnostics, medical device, and digital health companies increasingly have reasons to collaborate across patient journeys.
These shifts create opportunities, but successful adoption requires evidence, affordability, trusted clinical workflows, and sustainable reimbursement.
The geographic opportunity
The longevity economy is often discussed primarily through the lens of wealthy markets. That perspective is incomplete.
As ageing accelerates across emerging economies, demand for accessible diagnostics, essential medicines, chronic disease management, and scalable care infrastructure will grow.
However, companies cannot simply export high-income-market business models into environments with different purchasing power, healthcare financing, and delivery capabilities. International expansion will require locally adapted products, distribution models, partnerships, and financing solutions.
The Global OneHealth view
Longevity should be approached as a strategic transformation of healthcare demand—not merely as another therapeutic or consumer wellness category.
For established healthcare companies, it calls for a reassessment of portfolios and care pathways. For HealthTech innovators, it creates opportunities to address unmet needs in prevention, monitoring, and care coordination. For investors, it offers exposure to structural demand growth, provided that business models can demonstrate economic and clinical value. And for governments, it makes collaboration with the private sector increasingly important.
The next generation of healthcare leaders will compete not only on their ability to treat disease, but on their ability to support healthier lives over longer periods.
Sources and reference links
Figures and context are drawn from the source above. Strategic interpretation and visuals are Global OneHealth editorial analysis.
The Global OneHealth View — From Insight to Action.
← All articles